Generex Biotechnology Signs Letters of Intent to Establish NuGenerex Health MSO with Arizona Endocrinology Center & Paradise Valley Family Medicine


You May Also Like

Arbutus Presents Corporate Update on Key Milestones

First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid InhibitorAll-Oral Combination ...

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitisand Peanut Allergy ...